Maziar Mike Doustdar adjusted his microphone in Plainsboro, N.J. on Wednesday morning. The Novo Nordisk CEO was speaking to analysts during an earnings call. He reported that the Wegovy pill has already reached 1 million patients in the United States. Sales for the first quarter hit $355 million, shattering previous expectations. "It is no secret that the Wegovy pill is off to a record-breaking start," Doustdar said. This corporate success coincides with a new federal policy. The Medicare GLP-1 Bridge will begin on July 1, 2026. Eligible Medicare patients living with obesity will have access to the medication for a $50 monthly copay. The Centers for Medicare & Medicaid Services confirmed the subsidy on Thursday. This is the metabolic divide in action. While seniors in the U.S. receive federal support, a generic version of semaglutide is launching in Canada. The Canadian market will serve as a test case for future price erosion. New prescription pills like Foundayo are also hitting the shelves. Foundayo is a needle-free alternative to injectable treatments like Zepbound. Phase 3 study results show the pill can help patients lose 11% of their body weight. High-dose trials of Wegovy are pushing those numbers to 21%. We are witnessing the gating of physiological health behind a corporate subscription model. The state is subsidizing the cost of entry, but the pharmaceutical giants maintain control of the supply. The subscription body is the new frontier of labor and class. For those who can afford the copay, metabolic health is a monthly delivery. For the rest, it remains a luxury beyond reach.